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EGR-1 is Regulated by N-Methyl-D-Aspartate-Receptor
Stimulation and Associated with Patient Survival in Human High
Grade Astrocytomas
Abstract
Early growth response-1 (EGR-1) is considered a central regulator in tumor cell proliferation, migration
and angiogenesis and a promising candidate for gene therapy in human astrocytomas. However,
conflicting data have been reported suggesting that both tumor promoting and anti-tumor activity of
EGR-1 and its regulation, expression and prognostic significance still remain enigmatic. Our study
explored EGR-1 expression and regulation in astrocytomas and its association with patient survival. As
we detected two EGR-1 mRNA variants, one containing a N-methyl-D-aspartate-receptor (NMDA-R)
responsive cytoplasmic polyadenylation element (CPE), further experiments were performed to
determine the functional role of this pathway. After NMDA stimulation of SV-FHAS and neoplastic
astrocytes, real-time polymerase chain reaction showed an increase of the CPE, containing EGR-1 splice
variant only in astrocytoma cells. The surface expression and functionality of NMDA-R were
demonstrated by flow cytometric analysis and measurement of increased intracellular Ca(2+). EGR-1
was mainly restricted to tumor cells expressing NMDA-R and significantly up-regulated in astrocytic
tumors compared with normal brain. Further, EGR-1 expression was significantly (P < 0.007) associated
with enhanced patient survival and was an independent prognostic factor in multivariate analysis in high
grade astrocytomas. The NMDA-R-mediated EGR-1 expression, therefore, seems to be a promising
target for novel clinical approaches to astrocytoma treatment.
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Abstract 
Early growth response-1 (EGR-1) is considered a central regulator in tumor cell 
proliferation, migration and angiogenesis and a promising candidate for gene therapy 
in human astrocytomas. However, conflicting data have been reported suggesting 
both tumor promoting and antitumor activity of EGR-1 and its regulation, expression 
and prognostic significance still remain enigmatic. Our study explored EGR-1 
expression and regulation in astrocytomas and its association with patient survival. 
Since we detected two EGR-1 mRNA variants, one containing a NMDA receptor 
(NMDA-R) responsive cytoplasmic polyadenylation element (CPE), further 
experiments were performed to determine the functional role of this pathway. After 
NMDA stimulation of SV-FHAS and neoplastic astrocytes, real-time PCR showed an 
increase of the CPE containing EGR-1 splice variant only in astrocytoma cells. The 
surface expression and functionality of NMDA-R were demonstrated by flow 
cytometric analysis and measurement of increased intracellular Ca2+. EGR-1 was 
mainly restricted to tumor cells expressing NMDA-R and significantly upregulated in 
astrocytic tumors compared to normal brain. Further, EGR-1 expression was 
significantly (p<0.007) associated with enhanced patient survival and was an 
independent prognostic factor in multivariate analysis in high grade astrocytomas. 
The NMDA-R-mediated EGR-1 expression therefore seems to be a promising target 
for novel clinical approaches to astrocytoma treatment. 
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Introduction 
Despite improvement of surgical treatment and progress in radio- and 
chemotherapeutical strategies, the median survival times in diffuse astrocytomas 
remains as low as 1.6 years in anaplastic astrocytoma and only 0.4 years in 
glioblastoma (23). The migratory and proliferative capacity of astrocytomas which is 
accused to be at least partly responsible for the poor prognosis might be associated 
with Ca2+ permeable glutamate receptors (13, 20, 26). Along those lines, glutamate 
levels in human gliomas correlate with the degree of cell proliferation (2). Cellular 
mechanisms linking glutamate receptors to stimulation of migration and proliferation 
so far remain elusive but may include the immediate early gene EGR-1 (“early growth 
response-1”; also known as Krox24, Zif268, NGFI-A, Zenk, tis8, etr103 or d2) which 
is regulated upon glutamate receptor activation (5, 8, 30). However, in tumor cells 
EGR-1 may both, stimulate and suppress malignant progression. In glioblastoma cell 
lines EGR-1 binds to GC-rich sites of the human TGF-beta1 promotor leading to 
decreased proliferation and suppressed transformation. At the same time tumor cell 
migration is stimulated via activation of fibronectin (4, 18). In carcinoma cell lines, 
EGR-1 protein expression seems to be responsible for various features of tumor 
progression such as proliferation, migration, chemoinvasion and angiogenesis (7, 22, 
23). In contrast, sustained expression of EGR-1 in endothelial and fibrosarcoma cells 
blocks angiogenesis and tumor growth (19). In glioma cell lines EGR-1 may 
downregulate cyclin D1 and may thus exert a tumor suppressing function (27). In 
prostatic cancer, EGR-1 expression increases with the grade of malignancy (6). In 
nephroblastomas enhanced EGR-1 expression is associated with an unfavourable 
clinical prognosis (9). In contrast, in human breast and lung cancer, EGR-1 
expression decreases with the grade of malignancy (11, 16). Tumor suppressor 
 3
capacity of EGR-1 is further suggested by (i) direct transactivation of the PTEN gene, 
(ii) induction of p53 and (iii) binding of transcription factor c-Jun leading to increased 
pro-apoptotic activity (17, 32). EGR-1 activation could be mediated by NMDA-R (N-
methyl D-aspartate-receptor) stimulation since the EGR-1 gene possesses two 
different potential NMDA-R-responsive cytoplasmic polyadenylation elements (CPE1 
and CPE2) which are located close to the polyadenylation signal (HEX) (Figure 1) 
(29). These CPEs are responsible for the post-transcriptional translation of mRNAs 
that probably belong to a dormant cytoplasmic mRNA pool (21, 33). Signal 
transduction upon NMDA-R stimulation is mediated by the activation of the Aurora 
kinase which in turn phosphorylates the CPE binding protein (CPEB) which is 
required for a polyadenylation-dependent translation (12). Until now it is not clear 
how EGR-1 expression is regulated and why it exerts a dual role in astrocytomas. 
Further it remains to be established how the prognosis of astrocytomas may be 
related to the EGR-1 expression. In the present study, we therefore address the 
NMDA-R dependent regulation and prognostic impact of EGR-1 expression in human 
astrocytomas. 
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Materials and Methods 
 
Cell culture and stimulation 
The human glioblastoma cell lines LN229, LN428, U158, U251, U373 (kindly 
provided by N. de Tribolet, Lausanne, Switzerland) and the immortalized astrocytic 
cell line SV-FHAS (kindly provided by A. Muruganandam, Ottawa, Canada) were 
grown in DMEM supplemented with 10% fetal bovine serum and antibiotics 
(penicillin/streptomycin) under standard cell culture conditions. LN229 or SV-FHAS 
were either treated with 10 µM NMDA or with 50 mM KCl and assessed for viability 
and Egr-1 expression at 0, 10 and 30 min after exposure. KCl was applied as an 
unspecific stimulating agent. Additionally, cellular viability was tested by CASY cell 
counter and analyzer systems. For each time point 1 million cells were collected and 
frozen for further analysis. 
 
Primary glioblastoma cell culture 
Ex vivo glioma cell cultures, passages 4 to 9 of 5 glioblastoma patients were 
generated after tumour resection at the University Hospital of Zürich as previously 
described (24). All procedures were conducted in accordance with the Declaration of 
Helsinki and approved by the ethics committee of the Canton Zürich. The diagnoses 
were confirmed at the Institute of Neuropathology, University Hospital of Zürich. 
 
Real-time RT-PCR: 
Total RNA was harvested from the tissue culture cells by using Trizol Reagent®. 
Consecutively, 1 µg of every RNA sample was reverse-transcribed using Superscript 
II® in the same run. PCR was performed with standard protocols using SYBRGreen® 
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as fluorescent detection dye in a Biorad iCycler®. Standard curves for 5 2-fold 
dilutions of a reference RNA sample were generated to determine the PCR efficiency 
under the experimental conditions for the different transcripts and the housekeeping 
gene (GAPDH). All PCR reactions for a given sample were pipetted in triplicates in 
order to control the variability of the PCR amplification. The 2 Egr-1 variants were 
detected by GenBank research. The primer pairs used were the following (sv – short 
variant; lv – long variant): 
 
Egr1-sv_for.:  5’-AAAGTTTCACGTCTTGGTGCC-3’,  
Egr1-sv_rev.: 5’-GCTCAGCTCAGCCCTCTTCC-3’,  
Egr-lv_for.:  5’GGCTTATAAACACATTGAATGCG-3’,  
Egr-lv_rev.:   5’ACACCACATATCCCATGGGC-3’. 
Gapdh_for:  5’-TCA ACA GCG ACA CCC ACT CC-3’,  
Gapdh_rev:   5’-TGA GGT CCA CCA CCC TGT TG-3’. 
 
Flow cytometry  
Glioma cell lines and primary glioblastoma cells were analyzed for the expression of 
NMDA-R 1, the key receptor subunit of the heteromeric NMDA-R using flow 
cytometry. The cells were washed twice with flow cytometry buffer (PBS w/o Ca, Mg, 
2 mM EDTA, 0.5% BSA) and stained with either PE-labelled mouse IgG2a (BD 
Pharmingen, Heidelberg, Germany) for isotype control or with mouse monoclonal 
IgG2a anti-NMDA-R 1 antibody (Chemicon International, Temecula, CA, USA). Cells 
were incubated on ice for 30 min in the dark and washed twice with cold flow 
cytometry buffer (3.5 ml, 350 g, 7 min) before they were analyzed on a FACS Calibur 
flow cytometer. The cytometer was equipped with a 488 nm argon-ion laser and 635 
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nm red diode laser and Cell Quest 3.3 Software (BD Biosciences). The specific 
fluorescence index (SFI) was calculated as the ratio of the mean fluorescence values 
obtained with the specific NMDA-R antibody and the isotype control antibody.  
 
Measurement of intracellular Ca2+
Fura-2 fluorescence was utilized for cytosolic Ca2+ determinations (31). LN229 cells 
were loaded with Fura-2 (2.5µM- Molecular Probes, Goettingen, Germany) for 30 min 
at 37°C. Fluorescence measurements were carried out with an inverted phase-
contrast microscope (Axiovert 100, Zeiss, Oberkochen, Germany). Cells were excited 
alternatively at 340 and 380 nm and the light was deflected by a dichroic mirror into 
the objective (Fluar 40×/1.30 oil, Zeiss, Oberkochen, Germany). Emitted 
fluorescence intensity was recorded at 505 nm and data acquisition was performed 
by Axon Imaging Workbench (Axon Instruments, Foster City, CA, USA). Experiments 
were made prior to, during and following exposure to Ca2+ free solution (5 mM EGTA 
added). 
 
Patients and tissues 
We investigated a total of 193 brain tumor samples obtained from the brain tumor 
bank of the Institute of Brain Research (Neuropathology), University Tuübingen, from 
patients who underwent surgical treatment from 1993 to 2003. The specimens 
consisted of 26 WHO grade I (pilocytic), 37 WHO grade II and 52 grade III 
astrocytomas and 78 primary glioblastomas (WHO grade IV astrocytoma). 23 
autopsy cases from an established normal brain bank were also included. The 
pathological diagnoses were confirmed by at least two neuropathologists. The 
histopathological typing and grading was done according to the WHO criteria for 
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tumors of the nervous system (14). Glioma patients were followed for up to 12.6 
years. Within this time frame 102 patients died after a mean survival of 22.2 months 
(range 1-151) whereas 78 were still alive with a mean follow up of 44.4 months 
(range 1-136). 13 patients were lost to follow-up immediately after operation, so this 
population could not be integrated into the Kaplan-Meier survival analysis. For age-
stratified groups, patients were divided by median split. In the group of pilocytic 
astrocytomas only one patient died during the time of observation, therefore WHO 
grade I astrocytomas were not taken into account for survival analysis. 
 
Tissue microarray (TMA) 
TMA composite paraffin blocks were constructed by extracting cylindrical tissue core 
biopsies from different paraffin donor blocks and re-embedding these into a pre-
punched hole on a single recipient (microarray) paraffin block at defined array 
coordinates (15). Using this technique, representative tissue sections were extracted 
and prepared as TMA (Beecher Instruments, Inc., Sun Prairie; WI, USA) with a core 
diameter of 600 µm. Prior to this TMA construction a hematoxylin & eosin (HE) 
stained slide of each block was analyzed to avoid inappropriate regions (e.g. 
necrosis, hemorrhage) on the TMA slides. The TMA blocks were then cut with a 
microtome (3 µm thickness) and placed on SuperFrost Plus slides (Microm 
International, Walldorf, Germany).  
 
Immunohistochemistry 
All specimens were fixed in 4% formalin (pH 7.4), embedded in paraffin followed by 
preparation as TMA. Immunohistochemical stainings were performed according to 
standard protocols. The following primary antibodies were used: rabbit polyclonal 
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anti-Egr1 against the carboxy terminus (dilution: 1:200; Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA) followed by a biotinylated secondary anti-rabbit F(ab‘)2 
fragments (DAKO Cytomation, Hamburg, Germany). Exemplarily, double labeling 
was performed with Dako EnVision using DAB (1:500; GFAP; dilution: 1:500; 
Chemicon, Temecula, CA, USA) and Fast Red (EGR-1) as chromogens. For 
controls, the primary antibodies were omitted. 
 
Light microscopy and counting 
Evaluation of the immunohistochemical stainings and photographic documentation 
was performed using an Olympus Vanox AH-3 light microscope. To quantify the 
reaction 200 cells per sample were counted. In the tumor we excluded endothelial, 
neuronal, parenchymal inflammatory and intra-luminal cells by cellular morphology. 
 
Immunofluorescence 
Tumor tissue sections were double stained with mouse monoclonal IgG2a anti-
NMDA-R 1 antibody (dilution: 1:250; Chemicon) and EGR-1 (dilution: 1:200; Santa 
Cruz Biotechnology). After deparaffinization, slides were incubated in citrate buffer 
(pH 6.0), for 30 min using microwave heat treatment. For detection of antibody 
binding with fluorochrome-conjugated secondary antibody, the sections were blocked 
by incubation for 30 min with 5% (w/v) skimmed milk, 0.3% (w/v) Triton X-100 (Serva, 
Heidelberg, Germany) and 0.4% (w/v) NaN3 in TBS. Antibodies were diluted in the 
same solution and sections were incubated overnight at 4°C. After three washes in 
TBS for 10 min, sections were incubated for 45 min with the secondary antibody at 
room temperature. The secondary antibodies labelled with cyanin-derivative dye Cy2 
(dilution: 1:50) and Cy3 (1:100) were purchased from Dianova (Hamburg, Germany). 
 9
Following washes in TBS, nuclei of the glioma cells were stained with SYTOX green 
(dilution 1:1000; Invitrogen, Karlsruhe, Germany). After further washes in TBS, glass 
slides were mounted in glycerol. For controls, the primary antibodies were omitted. 
Fluorescence was visualized with a confocal laser scanning microscope (Axiovert 
135M, Zeiss, Oberkochen, Germany) and images were processed using Adobe 
Photoshop (version 6.0, Adobe, Mountain View, CA, USA). 
 
Statistical analysis 
For the analysis of PCR data, we processed the raw data CT values by calculating 
mean normalized expression (MNE) values which reflect the relative expression of a 
target to the housekeeping gene (28). Statistical analysis was performed using a pair 
wise fixed allocation randomization test® which has particularly been designed for 
the evaluation of quantitative real-time PCR results. The average coefficient of 
variation of the triplicates was 12%. Accordingly, a difference of more than 55% 
between two samples had a statistical power of 95%. We therefore only assigned 
significance to differences which were greater than 55%. The significance levels 
were the following: p < 0.05 (*); p< 0.01 (**); p < 0.001 (***). 
For the analysis of immunohistochemical EGR-1 stainings we used an analysis of 
variance (ANOVA) with subsequent Tukey HSD test with a global significance level 
of 5% after arcsine transformation of the EGR-1 positive fractions. The results were 
backtransformed in order to obtain the means and the 95% confidence intervals (CI) 
of the means. For the adjustment of the p-values due to multiple testing we used the 
method of Bonferroni-Holm. To analyze patient survival in high grade astrocytomas 
(WHO grade III and IV), we performed an exponential parametric survival fit. To 
describe patient survival starting from the day of operation, a univariate survival 
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analysis using product limit (Kaplan-Meier) life table was used and tested by the log-
rank method. Samples were stratified by protein expression into two groups of 
approximately equal size (high and low expression). Survival data were analyzed 
controlling for EGR-1 expression, patient age, WHO grade, gender, Karnofsky 
performance score, localisation, extent of resection and edema using the Cox 
proportional hazard model. Since there were only few deaths among patients with 
WHO grade I and II astrocytomas, these grades were excluded from the survival 
analysis. Age was included as a continuous variable. The KPS was dichotomized 
such that values less or equal to 80 and more than 80 were combined. The extent of 
resection (full or partial resection), gender (female/male) and localisation 
(supratentorial/infratentorial) were included as dichotomous variables. The edema 
level was analyzed in pre-operative T2 MRI scans in most cases or – if no MRI was 
available – in CCT scans. Edema levels were classified as follows: no = 0; low = 1; 
high = 2. Edema scores were analyzed in cooperation with the Department of 
Neuroradiology (University of Tübingen). JMP IN was used for statistical analysis 
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Results 
Predominantly CPE-containing EGR-1 variants increase upon NMDA stimulation 
Under non-activating conditions the expression of Egr-1sv (short variant) is about 5-
fold higher than the expression of Egr-1lv (long variant) (Figure 1, 2) in both the 
malignant glioma cell line LN229 and the immortalized astrocytic cell line SV-FHAS. 
After 10 min treatment with NMDA only the glioma cell line LN229 showed a 
significant 8.6-fold induction of Egr-1lv and a less pronounced 2.2-fold induction of 
Egr-1sv (Figure 2). While Egr-1lv still showed a significant 3.3-fold increase at 30 
min, Egr-1sv was insignificantly decreased 1.7-fold at this point. Depolarization with 
KCl induced similar but less pronounced effects in LN229 (Figure 2 A,B). In contrast, 
SV-FHAS cells only responded to depolarization with KCl whereas no significant 
increase was detected after NMDA stimulation. Cell viability was not influenced in a 
relevant manner by the experimental conditions at each time point (data not shown). 
 
Glioblastoma cells express the NMDA receptor 
To address the question to what extent astrocytic tumor cells express NMDA 
receptors at the cell surface, we investigated LN229 by flow cytometry. About 3% of 
all measured tumor cells strongly expressed NMDA-R on the cell surface. The other 
97% of LN229 cells showed a slight to moderate shift towards positive (SFI: 1.6) 
(Figure 3). In addition, 4 different cell lines and 5 patient-derived ex vivo 
glioblastoma cell cultures were assessed for their NMDA receptor expression by flow 
cytometry. The positively gated NMDA-R fractions reached 15.93% with a SFI of 1.83 
at maximum (Table 1). 
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 NMDA receptors are functionally active in LN229 glioma cells 
In order to determine the effect of NMDA treatment on the regulation of intracellular 
Ca2+ activity, we treated LN229 cells with 10 µM NMDA. This treatment is known to 
accelerate Ca2+ entry. The Fura-2 fluorescence ratio (340/380 nm) in the presence of 
extracellular Ca2+ was significantly lower before NMDA treatment (4.04 ± 0.37, n = 4) 
than after NMDA treatment (6.56± 0.32, n = 4) (Figure 4). These results show that 
the astrocytic tumor cell possess functionally active NMDA receptors. 
 
The nuclear expression of EGR-1 in human astrocytic tumors in vivo is strongly 
associated with NMDA receptor expression 
Immunofluorescent staining (n = 5 glioblastomas) showed that EGR-1 expression in 
human glioblastomas was restricted to the nucleus (Figure 5A). In double staining 
experiments, nuclear EGR-1 protein was mainly seen in cells strongly co-expressing 
the NMDA-R on the cell surface (Figure 5B).  
 
EGR-1 is significantly upregulated in human astrocytomas compared to normal CNS 
tissue 
In normal CNS tissue, classical immunohistochemistry revealed that about 9.4% (CI: 
6.7-12.5%) of all glial cells expressed EGR-1. In comparison to normal brain, all 
grades of astrocytic tumor displayed significantly higher EGR-1 levels. EGR-1 
expression was mainly found within the nuclei but occasionally also in the cytoplasm 
(Figure 6A, B). Double staining experiments showed that EGR-1-positive cells co-
expressed GFAP, corroborating their astrocytic origin (data not shown). The EGR-1 
expression levels were in a similar range throughout all WHO grades with a mean 
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expression rate of 16.9% (CI: 13.2-20.9%) in pilocytic astrocytomas, 15.5% (CI: 12.8-
18.4%) in diffuse and 17.8% (CI: 15.3-20.4%) in anaplastic astrocytomas and 19.4% 
(CI: 17.3-21.6%) in glioblastomas (Figure 6A, B).  
 
EGR-1 expression is significantly associated with enhanced patient survival in high 
grade astrocytomas and an independent prognostic factor in multivariate analysis 
As WHO grade III and IV astrocytomas showed no significant differences of EGR-1 
expression, a combined survival analysis was performed. The exponential parametric 
survival fit revealed a highly significant positive association of EGR-1 expression and 
patient survival in high grade astrocytic tumors (p=0.007) (Figure 7A). In a Kaplan-
Meier analysis where EGR-1 expression levels were split by median, the log rank test 
also demonstrated significantly longer survival rates for the group exhibiting higher 
EGR-1 expression levels (Figure 7B). In WHO grade II astrocytomas, the 
exponential parametric fit did not show a significant association of EGR-1 levels and 
patient survival (p=0.43). In the group of WHO grade I astrocytoma only one patient 
died, therefore pilocytic astrocytomas were not included in survival analysis. A 
multivariate analysis performed in high grade astrocytomas included EGR-1 
expression, patient age and WHO grade, which are both known to be strong 
predictors for patient survival in human astrocytomas, as well as gender, Karnofsky 
score, tumor localisation, extent of resection and edema score (Table 2). As 
previously reported, patient age had the strongest association with survival and was 
a stronger predictor of survival that WHO grade (3). Interestingly, for EGR-1, a 
significant association with survival remained in multivariate analysis (p=0.0224) with 
a p-value in the range of the WHO grade (0.0201). In contrast, gender, Karnofsky 
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score, tumor localisation, extent of resection and edema could not withstand the 
multivariate analysis.  
 
 
 
 
Discussion 
EGR-1 is known as a central regulator of expression due to its capacity to control a 
large number of different genes. However, the functional role of EGR-1 is still a 
matter of controversy. Being considered as a tumor suppressor gene in some tumors 
like breast or lung carcinoma, EGR-1 is perceived as a tumorigenic factor in other 
tumors such as prostate cancer (6, 11, 16, 22). Further, EGR-1 is of interest in 
diffusely infiltrating astrocytomas, since it has been shown to almost completely 
abolish tumor cell growth and migration, features that contribute to the incurability of 
these tumors (4). Therefore, EGR-1 was proposed as a most promising candidate for 
future gene therapy in human astrocytomas (4). Hence, the aim of the present study 
was to analyze the expression, regulation and prognostic power of EGR-1 in human 
astrocytomas. By GenBank research, we detected two potential NMDA-R-responsive 
cytoplasmic elements in the EGR-1 gene (Figure 1). Further, we recovered two 
different EGR-1 mRNA variants, of which only the elongated variant (EGR-1lv) 
possessed the potential NMDA-R responsive CPE. EGR-1lv showed early (after 10 
min) and highly significant increase in response to NMDA in LN229 glioma cells 
(Figure 2). In contrast, the shorter mRNA (EGR-1sv) only exhibited a very late 
increase. This effect was restricted to neoplastic astrocytes whereas SV-FHAS cells 
did not react to NMDA stimulation. These findings suggest that EGR-1 could be 
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regulated in a sequence-dependent manner in human astrocytomas. Flow cytometric 
analysis revealed that several astrocytomas cell lines and primary cultures express 
NMDA-R (Table 1, Figure 3). In additional experiments, we could demonstrate that 
these NMDA-Rs are functionally active in the same cell line (Figure 4). The NMDA-R 
pathway may thus be a functional regulatory element for EGR-1 expression in human 
astrocytomas. Localization of EGR-1 protein revealed a predominantly nuclear 
pattern which was strongly associated with membranous NMDA-R expression 
(Figure 5). It can be concluded that (i) NMDA-R seems to influence EGR-1 protein 
expression and (ii) the rapid upregulation and nuclear localization reflect the role of 
EGR-1 as fast and central regulator of gene expression. Along those lines EGR-1 
was recently shown to directly suppress different oncogenes and therefore the 
development of malignancies (10). As previously reported, we could demonstrate 
EGR-1 expression in normal brain glial cells (1). A surprising result was the 
upregulation of EGR-1 in all astrocytic WHO grades compared to normal brain since 
one would assume a decrease or even a loss of a tumor suppressor gene during 
malignant transformation (25). The constant EGR-1 levels among different WHO 
grades are difficult to explain. Since EGR-1 is a transcription factor which can be 
induced by various stimuli and is involved in many different pathways, the meaning of 
similar EGR-1 levels in both low and high grade astrocytomas might be due to a 
changing tumor micro-environment in neoplasms of different grades of malignancy. 
There are also other, to date unexplained molecular and histological features such as 
e.g. microvascular proliferations that are present in both WHO grade I and IV 
astrocytomas but do not carry the same predictive value. The highly significant 
association of EGR-1 expression with prolonged patient survival in high grade 
astrocytomas supports the hypothesis of a tumor suppressive capacity of EGR-1 that 
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is still functional after malignant transformation of astrocytic cells. The positive 
association of EGR-1 with patient survival in human high grade astrocytic tumors is in 
line with the results of esophageal squamous cell carcinomas (34). In high grade 
astrocytomas, EGR-1 remained a significant independent predictor of patient survival 
in multivariate analysis reaching a similar significance as the WHO grade. Both 
factors were inferior only to patient age which is known as a very powerful factor 
influencing patient survival in human astrocytomas (3). Even though EGR-1 
DNAzymes suppressed tumor proliferation, migration and angiogenesis in breast 
cancer cell lines, these promising results probably can not without reservations be 
translated to human astrocytic tumors (7). Other tumor suppressive regulatory 
mechanisms of EGR-1 seem to be stronger than the suggested tumorigenic effects. 
The blockage of glutamate receptors like AMPA receptors have been suggested as a 
possible therapeutic strategy for the prevention of astrocytoma invasion (13). Our 
results indicate that there is no basis for such attempts concerning the NMDA-R 
EGR-1 axis. Therefore, further studies are needed to elucidate the dichotomic gene 
regulatory function of EGR-1 in human astrocytomas. 
  
Acknowledgments 
 
This work was supported by grants from the Interdisciplinary Center of Clinical 
Research Tübingen (fortüne-programm) to P. Simon.  
  
 
 
 
 17
References 
1. Beckmann AM, Wilce PA. Egr transcription factors in the nervous system. 
Neurochem Int 1997; 31(4):477-510. 
2. Bianchi L, De Micheli E, Bricolo A, Ballini C, Fattori M, Venturi C, et al. 
Extracellular levels of amino acids and choline in human high grade gliomas: 
an intraoperative microdialysis study. Neurochem Res 2004; 29(1):325-34. 
3. Burger PC, Green SB. Patient age, histologic features, and length of survival 
in patients with glioblastoma multiforme. Cancer 1987; 59(9):1617-25. 
4. Calogero A, Lombari V, De Gregorio G, Porcellini A, Ucci S, Arcella A, et al. 
Inhibition of cell growth by EGR-1 in human primary cultures from malignant 
glioma. Cancer 2004; Cell Int. 4(1):1. 
5. Cole AJ, Saffen DW, Baraban JM, Worley PF. Rapid increase of an immediate 
early gene messenger RNA in hippocampal neurons by synaptic NMDA 
receptor activation. Nature 2002; 340(6233):474-6. 
6. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ. Expression of 
early growth response genes in human prostate cancer. Cancer Res 1998; 
58(11):2461-8. 
7. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Transcription 
factor Egr-1 supports FGF-dependent angiogenesis during neovascularization 
and tumor growth. Nat Med 2003; 9(8):1026-32. 
8. Fischer AJ, McGuire JJ, Schaeffel F, Stell WK. Light- and focus-dependent 
expression of the transcription factor ZENK in the chick retina. Nat Neurosci 
1999; 2(8):706-12. 
9. Ghanem MA, Van der Kwast TH, Den Hollander JC, Sudaryo MK, Oomen MH, 
Noordzij MA, et al. Expression and prognostic value of Wilms' tumor 1 and 
 18
early growth response 1 proteins in nephroblastoma. Clin Cancer Res 2000; 
6(11):4265-71. 
10. Gibbs JD, Liebermann DA, Hoffman B. Egr-1 abrogates the E2F-1 block in 
terminal myeloid differentiation and suppresses leukemia. Oncogene 2007; 
Jun 25; [Epub ahead of print] 
11. Huang RP, Fan Y, Belle ID, Niemeyer C, Gottardis MM, Mercola D, et al. 
Decreased Egr-1 expression in human, mouse, and rat mammary cells and 
tissues correlates with tumor formation. Int J Cancer 1997; 72: 102–109. 
12. Huang YS, Jung MY, Sarkissian M, Richter JD. N-methyl-D-aspartate receptor 
signaling results in Aurora kinase-catalyzed CPEB phosphorylation and alpha 
CaMKII mRNA polyadenylation at synapses. EMBO J 2002; 21(9):2139-48. 
13. Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada N, Hagimura N, Okado H, et al. 
Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and 
induces apoptosis in human glioblastoma cells. Nat Med 2002; 8(9):971-8. 
14. Kleihues P, Cavenee WK. Pathology and Genetics of Tumours of the Nervous 
system (IARC Press Lyon) 2000. 
15. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et 
al. Tissue microarrays for high-throughput molecular profiling of tumor 
specimens. Nat Med 1998; 4:844-7. 
16. Levin WJ, Press MF, Gaynor RB, Sukhatme VP, Boone TC, Reissmann PT, et 
al. Expression patterns of immediate early transcription factors in human non-
small cell lung cancer. The Lung Cancer Study Group. Oncogene 1995; 11: 
1261–1269. 
 19
17. Liu C, Rangnekar VM, Adamson E, Mercola D. Suppression of growth and 
transformation and induction of apoptosis by EGR-1. Cancer Gene Ther 1998; 
5(1):3-28. 
18. Liu C, Yao J, Mercola D, Adamson E. The transcription factor EGR-1 directly 
transactivates the fibronectin gene and enhances attachment of human 
glioblastoma cell line U251. J Biol Chem 2000; 275(27):20315-23. 
19. Lucerna M, Pomyje J, Mechtcheriakova D, Kadl A, Gruber F, Bilban M, et al. 
Sustained expression of early growth response protein-1 blocks angiogenesis 
and tumor growth. Cancer Res 2006; 66(13):6708-13. 
20. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine 
glutamate signaling promotes glioma cell invasion. Cancer Res 2007; 67 : 
9463-71. 
21. Mendez R, Richter JD. Translational control by CPEB: a means to the end. 
Nat Rev Mol Cell Biol 2001; 2(7):521-9. 
22. Mitchell A, Dass CR, Sun LQ, Khachigian LM. Inhibition of human breast 
carcinoma proliferation, migration, chemoinvasion and solid tumour growth by 
DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids 
Res 2004; 32(10):3065-9. 
23. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, 
and genetic alterations in astrocytic and oligodendroglial gliomas. J 
Neuropathol Exp Neurol 2005; 64(6):479-89. 
24. Rodak R, Kubota H, Ishihara H, Eugster HP, Könü D, Möhler H, Yonekawa Y, 
Frei K. Induction of reactive oxygen intermediates-dependent programmed cell 
death in human malignant ex vivo glioma cells and inhibition of the vascular 
 20
endothelial growth factor production by taurolidine. J Neurosurg 2005; 
102:1055-68. 
25. Ronski K, Sanders M, Burleson JA, Moyo V, Benn P, Fang M. Early growth 
response gene 1 (EGR1) is deleted in estrogen receptor-negative human 
breast carcinoma. Cancer 2005; 104(5):925-30. 
26. Rzeski W, Turski L, Ikonomidou C. Glutamate antagonists limit tumor growth. 
Proc Natl Acad Sci 2001; 98(11):6372-7. 
27. Shin SY, Kim CG, Hong DD, Kim JH, Lee YH. Implication of Egr-1 in 
trifluoperazine-induced growth inhibition in human U87MG glioma cells. Exp 
Mol Med 2004; 36(4):380-6. 
28. Simon P. Q-Gene: processing quantitative real-time RT-PCR data. 
Bioinformatics 2003; 19(11):1439-40. 
29. Simon P, Schott K, Williams RW, Schaeffel F. Posttranscriptional regulation of 
the immediate-early gene EGR1 by light in the mouse retina. Eur J Neurosci 
2004; 20(12):3371-7. 
30. Snyder-Keller A, Chandra R, Lin Y, Mitchell ES. Basal EGR-1 (zif268, NGFI-A, 
Krox-24) expression in developing striatal patches: role of dopamine and 
glutamate. Brain Res 2002; 958(2):297-304. 
31. Tanneur V, Ilgaz D, Duranton C, Fillon S, Gamper N, Huber SM, et al. Time-
dependent regulation of capacitative Ca2+ entry by IGF-1 in human embryonic 
kidney cells. Pflugers Arch 2002; 445(1):74-9.  
32. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, et al. The 
Egr-1 transcription factor directly activates PTEN during irradiation-induced 
signalling. Nat Cell Biol 2001; 3(12):1124-8. 
 21
33. Wells DG, Dong X, Quinlan EM, Huang YS, Bear MF, Richter JD, et al. A role 
for the cytoplasmic polyadenylation element in NMDA receptor-regulated 
mRNA translation in neurons. J Neurosci 2001; 21(24):9541-8. 
34. Wu MY, Wu XY, Li QS, Zheng RM. Expression of Egr-1 gene and its 
correlation with the oncogene proteins in non-irradiated and irradiated 
esophageal squamous cell carcinoma. Dis Esophagus 2006; 19(4):267-72. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22
  
 
Figure Legends 
Figure 1: Schematic illustration of the EGR-1 gene and mRNAs with two full-
sequence entries found in GenBank. At the 3’UTR, two potential NMDA receptor-
responsive cytoplasmic elements (CPE1 and CPE2) in close relation to 
polyadenylated signal (HEX) are depicted. These CPEs are only found in one EGR-1 
mRNA variant. Phylogenetic conservation values are indicated. 
 
Figure 2: Expression of Egr-1sv (A, C) and Egr-1lv (B, D) in both the malignant 
glioma cell line LN229 (A, B) and the immortalized astrocytic cell line SV-FHAS (C, 
D) under resting conditions and after stimulation with NMDA or KCl. Cell viability was 
not influenced in a relevant manner by the experimental conditions at each time point 
(data not shown). 
 
Figure 3: Flow cytometry of NMDA receptor expression in LN229 glioma cells. The 
panels show flow cytometric analysis of fluorescence/side scatter (FL1/SSC) for 
isotype control (upper panel) and analysis of LN229 cells after incubation with the 
mouse monoclonal IgG2a anti-NMDA-R 1 antibody (middle panel). 2.91% of LN229 
cells stain positive for NMDA-R 1 and can be grouped in high, medium, low positive 
cells for FL1. FL1 is illustrated as histograms (lower panel) comparing isotype control 
(open bold line) and NMDA-R antibody (filled). 96.96% of the cells show a slight shift 
towards positive, but remain negative for FL1. X-axis: number of events, Y-axis: 
fluorescence intensity. Shown are data from one representative experiment (n=3). 
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Figure 4:  
Increase of Ca2+ entry into LN229 cells.  
(A) Representative original tracings showing the Fura-2 fluorescence ratio (340/380 
nm) in Fura 2 loaded LN cells 229 exposed initially to Ca2+ free Ringer (0 Ca2+, 5 mM 
EGTA), to Ringer containing 1 mM extracellular Ca2+. During exposure to Ca2+ 
solution NMDA (10 µM) was added to stimulate the NMDA receptors. (B) Mean (± 
SEM; n = 4) of the Fura-2 fluorescence ratio after incubation as in (A) in Ca2+ free 
Ringer, in Ca2+ containing extracellular fluid, and in Ca2+ and NMDA containing 
Ringer. * indicates significant (P ≤ 0.05, ANOVA) difference to respective value prior 
to removal of Ca2+. 
 
Figure 5: Immunofluorescence of EGR-1 and NMDA receptor in human 
glioblastomas. (A) A strict nuclear localisation of EGR-1 in a subset of glioblastoma 
cells was detected (EGR-1: red; nuclear staining: Sytox green). Yellow staining 
reflects the co-expression of EGR-1 with the nuclear Sytox green staining. (B) 
Nuclear EGR-1 protein (green) is strongly associated with NMDA receptor (red) 
expression in human glioblastomas.  
  
Figure 6: EGR-1 immunohistochemistry. Two glioblastoma samples are depicted 
showing increased nuclear EGR-1 immunoreactivity (arrows in A and B) in areas with 
higher cellularity whereas tumor areas exhibiting lower cell density (asterisk in A) or 
even resembling mainly normal CNS tissue (asterisk in B) show less EGR-1 
positivity. 
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 Figure 7: Association of EGR-1 expression with patient survival in high grade 
astrocytomas (WHO grade III and IV). (A) Exponential parametric survival fit 
analyzing survival time (note log scale) in relation to EGR-1 expression (arcsine 
transformed % values) showed a highly significant positive association of patient 
survival with higher EGR-1 expression rates (p=0.007) (x-axis: EGR-1 expression; y-
axis: survival time). (B) Kaplan Meier analysis of the same data dichotomized by a 
median EGR-1 expression split revealed a significant prognostic benefit of patients 
with high EGR-1 levels (log rank: p=0.035; green line: high EGR-1 expression level; 
red: low EGR-1 expression level; n = 130). 
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